Potential of Inaccurate Cefiderocol Susceptibility Results: a CLSI AST Subcommittee Advisory
- PMID: 36946754
- PMCID: PMC10117095
- DOI: 10.1128/jcm.01600-22
Potential of Inaccurate Cefiderocol Susceptibility Results: a CLSI AST Subcommittee Advisory
Keywords: Clinical and Laboratory Standards Institute; antimicrobial susceptibility testing; cefiderocol.
Conflict of interest statement
The authors declare a conflict of interest. All authors are members of the Clinical and Laboratory Standards Institute Antimicrobial Susceptibility Testing Subcommittee. P.J.S., R.H., and M.J.S. are consultants to Shionogi, Inc.
References
-
- Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagace-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, karlowsky JA. 2019. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli. Drugs 79:271–289. doi:10.1007/s40265-019-1055-2. - DOI - PubMed
-
- Clinical and Laboratory Standards Institute. 2022. Performance standards for antimicrobial susceptibility testing; Thirty-Second Informational Supplement., M100-S32. CLSI, Wayne, PA.
-
- Clinical and Laboratory Standards Institute. 2021. 2021 Winter AST summary minutes. https://clsi.org/meetings/ast-file-resources/.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
